Secondary analysis of the phase 2 INSIGhT trial in MGMT-unmethylated glioblastoma: using matched external controls, abemaciclib (HR 1.00), neratinib (HR 0.93) and CC-115 (HR 0.88) showed no survival benefit, consistent with the original analyses.
Secondary analysisn = 234
Rudra Gupta et al. Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data